Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EXP017
- Development stage
- Unknown
- Lead developer
- ExpreS2ion Biotechnologies
- Modality
- Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
EXP017 is a virus-like particle (VLP) vaccine candidate designed for the prevention of malaria caused by *Plasmodium falciparum*. Developed by ExpreS2ion Biotechnologies in collaboration with the University of Oxford, the vaccine utilizes the proprietary ExpreS2 protein expression system (based on *Drosophila melanogaster* S2 cells) to produce the Reticulocyte-binding protein Homologue 5 (RH5) antigen. This antigen is displayed on a highly immunogenic mi3 VLP scaffold using SpyTag/SpyCatcher conjugation technology. RH5 is a highly conserved protein essential for the invasion of human erythrocytes by the malaria parasite. By inducing potent neutralizing antibodies that block the interaction between RH5 and its human receptor, Basigin (CD147), EXP017 aims to prevent the blood-stage infection responsible for clinical malaria symptoms.
- Other names
- RH5-VLP malaria vaccineRH-5-VLP malaria vaccineRH 5-VLP malaria vaccine
02
Targets
PfRH5
Beyond the preview
Go deeper on EXP017.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EXP017.